Sonnet Biotherapeutics Holdings Inc SONN

Consumer Cyclical Biotechnology

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.

NDAQ:SONN - Post by User

Sonnet Biotherapeutics Holdings Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Sep 25, 2024 5:47pm

31 Views

Post# 36241095

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

NEWS: $SONN Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitPRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stoc...SONN - Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3